March 13, 2020
Comments Off on Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Grade 3 treatment-related adverse events were observed in four (17 %) patients. CONCLUSIONS: The combination of IM and GEM is well tolerated in platinum-pemetrexed-pretreated MPM patients expressing PDGFR-β and/or cKIT by IHC, but it does not show a significant PFS benefit.March 12, 2020
Comments Off on A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Ongoing studies will further confirm the potential efficacy of ICIs for MPM, as observed across other malignancies. It is also crucial to identify any clinically useful predictive biomarkers that could reveal ICIs with maximal effects in MPM.March 11, 2020
Comments Off on Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.
It is estimated MPM will continue to cause serious morbidity and mortality in the UK late into the 21st century, and internationally, people continue to be exposed to asbestos. We aim to update the reader on current and future imaging strategies, which could aid early diagnosis of pleural malignancy and provide an update on staging and assessment of tumour response.March 6, 2020
Comments Off on The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.
Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival.
Our findings lead to a better characterization of MPM heterogeneity by identifying new significant associations between mutational status and histologic and molecular heterogeneity. Strikingly, we highlight the strong association between new mutations and overall survival.March 5, 2020
Comments Off on Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival.
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
CONCLUSIONS: The primary efficacy endpoint was reached with acceptable toxicity. Lurbinectedin showed promising activity regardless of histology, prior immunotherapy, or outcome on prior treatment.March 4, 2020
Biphasic or Mixed, Chemotherapy, Epithelioid, Full Archive, Immune-based Therapies, Pemetrexed (Alimta), Pleural, Sarcomatoid
Comments Off on Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
What is Mesothelioma?
Learn more about this fatal cancer, including the causes, symptoms, and treatments for both pleural and peritoneal tumors of the mesothelium at our parent site MesotheliomaCenter.
Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.
IMRT can thus be considered in well-selected patients in whom adequate survival following pleurectomy is expected. These data also support the initiation of the phase III NRG-LU006 trial of eP/D and chemotherapy with or without IMRT.March 3, 2020
Comments Off on Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
CONCLUSIONS: Our findings indicate that the use of immunotherapy in MPM warrants further investigation. Furthermore, the impressive clinical response obtained by our patient suggests that immune checkpoint inhibitors could help in the management of the disease after the failure of other treatments.March 2, 2020
Carboplatin, Cisplatin (Platinol ®), Epithelioid, Full Archive, Gemcitabine (Gemzar), Pemetrexed (Alimta), Pleural, Pleural Effusion, Pleurectomy/decortication
Comments Off on Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
An in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.
CONCLUSION: In this contest, MacroH2A. 1 overexpression supports its function as an epigenetic stabilizer that helps to establish and maintain differentiated states.February 28, 2020
Comments Off on An in vivo immunohistochemical study on MacroH2A.1 in lung and lymph-node tissues exposed to an asbestiform fiber.
Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study.
Results (SEER) 18 database for 2000-2014. Patients diagnosed in 1997-2013 with malignant epithelialFebruary 27, 2020
Comments Off on Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study.